Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated:  9/21/2017
UF Cancer Center at Orlando Health
mi
from
Orlando, FL
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated: 9/21/2017
UF Cancer Center at Orlando Health
mi
from
Orlando, FL
Click here to add this to my saved trials
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated:  9/21/2017
Saint Joseph's Hospital/Children's Hospital-Tampa
mi
from
Tampa, FL
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated: 9/21/2017
Saint Joseph's Hospital/Children's Hospital-Tampa
mi
from
Tampa, FL
Click here to add this to my saved trials
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated:  9/21/2017
University of Hawaii Cancer Center
mi
from
Honolulu, HI
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated: 9/21/2017
University of Hawaii Cancer Center
mi
from
Honolulu, HI
Click here to add this to my saved trials
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated:  9/21/2017
Lurie Children's Hospital- Chicago
mi
from
Chicago, IL
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated: 9/21/2017
Lurie Children's Hospital- Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated:  9/21/2017
Southern Illinois University School of Medicine
mi
from
Springfield, IL
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated: 9/21/2017
Southern Illinois University School of Medicine
mi
from
Springfield, IL
Click here to add this to my saved trials
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated:  9/21/2017
Indiana University Melvin and Bren Simon Cancer Center
mi
from
Indianapolis, IN
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated: 9/21/2017
Indiana University Melvin and Bren Simon Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated:  9/21/2017
University of Iowa - Holden Comprehensive Cancer Center
mi
from
Iowa City, IA
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated: 9/21/2017
University of Iowa - Holden Comprehensive Cancer Center
mi
from
Iowa City, IA
Click here to add this to my saved trials
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated:  9/21/2017
University of Kentucky, Markey Cancer Center
mi
from
Lexington, KY
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated: 9/21/2017
University of Kentucky, Markey Cancer Center
mi
from
Lexington, KY
Click here to add this to my saved trials
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated:  9/21/2017
Johns Hopkins University-Sidney Kimmel Cancer Center
mi
from
Baltimore, MD
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated: 9/21/2017
Johns Hopkins University-Sidney Kimmel Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated:  9/21/2017
Wayne State University/Karmanos Cancer Institute
mi
from
Detroit, MI
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated: 9/21/2017
Wayne State University/Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated:  9/21/2017
University of Minnesota, Masonic Cancer Center
mi
from
Minneapolis, MN
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated: 9/21/2017
University of Minnesota, Masonic Cancer Center
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated:  9/21/2017
Mercy Hospital Saint Louis
mi
from
Saint Louis, MO
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated: 9/21/2017
Mercy Hospital Saint Louis
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated:  9/21/2017
Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital
mi
from
New Brunswick, NJ
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated: 9/21/2017
Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated:  9/21/2017
Columbia University Herbert Irving Cancer Center
mi
from
New York, NY
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated: 9/21/2017
Columbia University Herbert Irving Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated:  9/21/2017
Montefiore Medical Center - Moses Campus
mi
from
The Bronx, NY
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated: 9/21/2017
Montefiore Medical Center - Moses Campus
mi
from
The Bronx, NY
Click here to add this to my saved trials
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated:  9/21/2017
UNC Lineberger Comprehensive Cancer Center
mi
from
Chapel Hill, NC
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated: 9/21/2017
UNC Lineberger Comprehensive Cancer Center
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated:  9/21/2017
Carolinas Medical Center / Levine Cancer Institute
mi
from
Charlotte, NC
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated: 9/21/2017
Carolinas Medical Center / Levine Cancer Institute
mi
from
Charlotte, NC
Click here to add this to my saved trials
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated:  9/21/2017
Novant Health Presbyterian Medical Center
mi
from
Charlotte, NC
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated: 9/21/2017
Novant Health Presbyterian Medical Center
mi
from
Charlotte, NC
Click here to add this to my saved trials
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated:  9/21/2017
Dayton Children's Hospital
mi
from
Dayton, OH
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated: 9/21/2017
Dayton Children's Hospital
mi
from
Dayton, OH
Click here to add this to my saved trials
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated:  9/21/2017
Natalie Warren Bryant Cancer Center at Saint Francis
mi
from
Tulsa, OK
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated: 9/21/2017
Natalie Warren Bryant Cancer Center at Saint Francis
mi
from
Tulsa, OK
Click here to add this to my saved trials
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated:  9/21/2017
Children's Oncology Group
mi
from
Philadelphia, PA
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated: 9/21/2017
Children's Oncology Group
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated:  9/21/2017
Vanderbilt University/Ingram Cancer Center
mi
from
Nashville, TN
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated: 9/21/2017
Vanderbilt University/Ingram Cancer Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated:  9/21/2017
UT Southwestern/Simmons Cancer Center-Dallas
mi
from
Dallas, TX
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated: 9/21/2017
UT Southwestern/Simmons Cancer Center-Dallas
mi
from
Dallas, TX
Click here to add this to my saved trials
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated:  9/21/2017
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
mi
from
Houston, TX
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated: 9/21/2017
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated:  9/21/2017
University of Vermont College of Medicine
mi
from
Burlington, VT
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated: 9/21/2017
University of Vermont College of Medicine
mi
from
Burlington, VT
Click here to add this to my saved trials
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated:  9/21/2017
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated: 9/21/2017
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Click here to add this to my saved trials
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated:  9/21/2017
Children¿s Hospital of Wisconsin
mi
from
Milwaukee, WI
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated: 9/21/2017
Children¿s Hospital of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC
ARMOR3-SV: A Phase 3, Randomized, Open Label, Multi-Center, Controlled Study of Galeterone Compared to Enzalutamide in Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic (M1) Castrate Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated:  9/21/2017
Pinnacle Oncology Hematology
mi
from
Scottsdale, AZ
A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC
ARMOR3-SV: A Phase 3, Randomized, Open Label, Multi-Center, Controlled Study of Galeterone Compared to Enzalutamide in Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic (M1) Castrate Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated: 9/21/2017
Pinnacle Oncology Hematology
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC
ARMOR3-SV: A Phase 3, Randomized, Open Label, Multi-Center, Controlled Study of Galeterone Compared to Enzalutamide in Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic (M1) Castrate Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated:  9/21/2017
University of Arizona Cancer Center
mi
from
Tucson, AZ
A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC
ARMOR3-SV: A Phase 3, Randomized, Open Label, Multi-Center, Controlled Study of Galeterone Compared to Enzalutamide in Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic (M1) Castrate Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated: 9/21/2017
University of Arizona Cancer Center
mi
from
Tucson, AZ
Click here to add this to my saved trials
A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC
ARMOR3-SV: A Phase 3, Randomized, Open Label, Multi-Center, Controlled Study of Galeterone Compared to Enzalutamide in Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic (M1) Castrate Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated:  9/21/2017
City of Hope
mi
from
Duarte, CA
A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC
ARMOR3-SV: A Phase 3, Randomized, Open Label, Multi-Center, Controlled Study of Galeterone Compared to Enzalutamide in Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic (M1) Castrate Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated: 9/21/2017
City of Hope
mi
from
Duarte, CA
Click here to add this to my saved trials
A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC
ARMOR3-SV: A Phase 3, Randomized, Open Label, Multi-Center, Controlled Study of Galeterone Compared to Enzalutamide in Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic (M1) Castrate Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated:  9/21/2017
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC
ARMOR3-SV: A Phase 3, Randomized, Open Label, Multi-Center, Controlled Study of Galeterone Compared to Enzalutamide in Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic (M1) Castrate Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated: 9/21/2017
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC
ARMOR3-SV: A Phase 3, Randomized, Open Label, Multi-Center, Controlled Study of Galeterone Compared to Enzalutamide in Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic (M1) Castrate Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated:  9/21/2017
UCLA Jonsson Comprehensive Cancer Center
mi
from
Los Angeles, CA
A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC
ARMOR3-SV: A Phase 3, Randomized, Open Label, Multi-Center, Controlled Study of Galeterone Compared to Enzalutamide in Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic (M1) Castrate Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated: 9/21/2017
UCLA Jonsson Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC
ARMOR3-SV: A Phase 3, Randomized, Open Label, Multi-Center, Controlled Study of Galeterone Compared to Enzalutamide in Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic (M1) Castrate Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated:  9/21/2017
Prostate Oncology Specialists, Inc.
mi
from
Marina Del Rey, CA
A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC
ARMOR3-SV: A Phase 3, Randomized, Open Label, Multi-Center, Controlled Study of Galeterone Compared to Enzalutamide in Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic (M1) Castrate Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated: 9/21/2017
Prostate Oncology Specialists, Inc.
mi
from
Marina Del Rey, CA
Click here to add this to my saved trials
A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC
ARMOR3-SV: A Phase 3, Randomized, Open Label, Multi-Center, Controlled Study of Galeterone Compared to Enzalutamide in Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic (M1) Castrate Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated:  9/21/2017
UC Davis Cancer Center
mi
from
Sacramento, CA
A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC
ARMOR3-SV: A Phase 3, Randomized, Open Label, Multi-Center, Controlled Study of Galeterone Compared to Enzalutamide in Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic (M1) Castrate Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated: 9/21/2017
UC Davis Cancer Center
mi
from
Sacramento, CA
Click here to add this to my saved trials
A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC
ARMOR3-SV: A Phase 3, Randomized, Open Label, Multi-Center, Controlled Study of Galeterone Compared to Enzalutamide in Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic (M1) Castrate Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated:  9/21/2017
San Bernardino Urological Associates
mi
from
San Bernardino, CA
A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC
ARMOR3-SV: A Phase 3, Randomized, Open Label, Multi-Center, Controlled Study of Galeterone Compared to Enzalutamide in Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic (M1) Castrate Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated: 9/21/2017
San Bernardino Urological Associates
mi
from
San Bernardino, CA
Click here to add this to my saved trials
A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC
ARMOR3-SV: A Phase 3, Randomized, Open Label, Multi-Center, Controlled Study of Galeterone Compared to Enzalutamide in Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic (M1) Castrate Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated:  9/21/2017
Urology Speciality Group
mi
from
Torrance, CA
A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC
ARMOR3-SV: A Phase 3, Randomized, Open Label, Multi-Center, Controlled Study of Galeterone Compared to Enzalutamide in Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic (M1) Castrate Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated: 9/21/2017
Urology Speciality Group
mi
from
Torrance, CA
Click here to add this to my saved trials
A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC
ARMOR3-SV: A Phase 3, Randomized, Open Label, Multi-Center, Controlled Study of Galeterone Compared to Enzalutamide in Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic (M1) Castrate Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated:  9/21/2017
University of Colorado Cancer Center Anschultz Cancer Pavilion
mi
from
Aurora, CO
A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC
ARMOR3-SV: A Phase 3, Randomized, Open Label, Multi-Center, Controlled Study of Galeterone Compared to Enzalutamide in Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic (M1) Castrate Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated: 9/21/2017
University of Colorado Cancer Center Anschultz Cancer Pavilion
mi
from
Aurora, CO
Click here to add this to my saved trials
A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC
ARMOR3-SV: A Phase 3, Randomized, Open Label, Multi-Center, Controlled Study of Galeterone Compared to Enzalutamide in Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic (M1) Castrate Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated:  9/21/2017
Urology Center of Colorado
mi
from
Denver, CO
A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC
ARMOR3-SV: A Phase 3, Randomized, Open Label, Multi-Center, Controlled Study of Galeterone Compared to Enzalutamide in Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic (M1) Castrate Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated: 9/21/2017
Urology Center of Colorado
mi
from
Denver, CO
Click here to add this to my saved trials
A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC
ARMOR3-SV: A Phase 3, Randomized, Open Label, Multi-Center, Controlled Study of Galeterone Compared to Enzalutamide in Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic (M1) Castrate Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated:  9/21/2017
Yale University School of Medicine
mi
from
New Haven, CT
A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC
ARMOR3-SV: A Phase 3, Randomized, Open Label, Multi-Center, Controlled Study of Galeterone Compared to Enzalutamide in Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic (M1) Castrate Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated: 9/21/2017
Yale University School of Medicine
mi
from
New Haven, CT
Click here to add this to my saved trials
A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC
ARMOR3-SV: A Phase 3, Randomized, Open Label, Multi-Center, Controlled Study of Galeterone Compared to Enzalutamide in Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic (M1) Castrate Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated:  9/21/2017
Boca Raton Community Hospital
mi
from
Boca Raton, FL
A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC
ARMOR3-SV: A Phase 3, Randomized, Open Label, Multi-Center, Controlled Study of Galeterone Compared to Enzalutamide in Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic (M1) Castrate Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated: 9/21/2017
Boca Raton Community Hospital
mi
from
Boca Raton, FL
Click here to add this to my saved trials
A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC
ARMOR3-SV: A Phase 3, Randomized, Open Label, Multi-Center, Controlled Study of Galeterone Compared to Enzalutamide in Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic (M1) Castrate Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated:  9/21/2017
Moffitt Cancer Center
mi
from
Tampa, FL
A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC
ARMOR3-SV: A Phase 3, Randomized, Open Label, Multi-Center, Controlled Study of Galeterone Compared to Enzalutamide in Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic (M1) Castrate Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated: 9/21/2017
Moffitt Cancer Center
mi
from
Tampa, FL
Click here to add this to my saved trials
A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC
ARMOR3-SV: A Phase 3, Randomized, Open Label, Multi-Center, Controlled Study of Galeterone Compared to Enzalutamide in Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic (M1) Castrate Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated:  9/21/2017
First Urology
mi
from
Jeffersonville, IN
A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC
ARMOR3-SV: A Phase 3, Randomized, Open Label, Multi-Center, Controlled Study of Galeterone Compared to Enzalutamide in Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic (M1) Castrate Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated: 9/21/2017
First Urology
mi
from
Jeffersonville, IN
Click here to add this to my saved trials
A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC
ARMOR3-SV: A Phase 3, Randomized, Open Label, Multi-Center, Controlled Study of Galeterone Compared to Enzalutamide in Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic (M1) Castrate Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated:  9/21/2017
Tulane Medical Center
mi
from
New Orleans, LA
A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC
ARMOR3-SV: A Phase 3, Randomized, Open Label, Multi-Center, Controlled Study of Galeterone Compared to Enzalutamide in Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic (M1) Castrate Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated: 9/21/2017
Tulane Medical Center
mi
from
New Orleans, LA
Click here to add this to my saved trials
A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC
ARMOR3-SV: A Phase 3, Randomized, Open Label, Multi-Center, Controlled Study of Galeterone Compared to Enzalutamide in Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic (M1) Castrate Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated:  9/21/2017
Regional Urology
mi
from
Shreveport, LA
A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC
ARMOR3-SV: A Phase 3, Randomized, Open Label, Multi-Center, Controlled Study of Galeterone Compared to Enzalutamide in Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic (M1) Castrate Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated: 9/21/2017
Regional Urology
mi
from
Shreveport, LA
Click here to add this to my saved trials
A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC
ARMOR3-SV: A Phase 3, Randomized, Open Label, Multi-Center, Controlled Study of Galeterone Compared to Enzalutamide in Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic (M1) Castrate Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated:  9/21/2017
University of Maryland Greenenbaum Cancer Center
mi
from
Baltimore, MD
A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC
ARMOR3-SV: A Phase 3, Randomized, Open Label, Multi-Center, Controlled Study of Galeterone Compared to Enzalutamide in Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic (M1) Castrate Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated: 9/21/2017
University of Maryland Greenenbaum Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC
ARMOR3-SV: A Phase 3, Randomized, Open Label, Multi-Center, Controlled Study of Galeterone Compared to Enzalutamide in Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic (M1) Castrate Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated:  9/21/2017
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC
ARMOR3-SV: A Phase 3, Randomized, Open Label, Multi-Center, Controlled Study of Galeterone Compared to Enzalutamide in Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic (M1) Castrate Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated: 9/21/2017
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC
ARMOR3-SV: A Phase 3, Randomized, Open Label, Multi-Center, Controlled Study of Galeterone Compared to Enzalutamide in Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic (M1) Castrate Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated:  9/21/2017
Walter Reed National Military Medical Center
mi
from
Bethesda, MD
A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC
ARMOR3-SV: A Phase 3, Randomized, Open Label, Multi-Center, Controlled Study of Galeterone Compared to Enzalutamide in Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic (M1) Castrate Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated: 9/21/2017
Walter Reed National Military Medical Center
mi
from
Bethesda, MD
Click here to add this to my saved trials
A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC
ARMOR3-SV: A Phase 3, Randomized, Open Label, Multi-Center, Controlled Study of Galeterone Compared to Enzalutamide in Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic (M1) Castrate Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated:  9/21/2017
Massachusetts General Hospital
mi
from
Boston, MA
A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC
ARMOR3-SV: A Phase 3, Randomized, Open Label, Multi-Center, Controlled Study of Galeterone Compared to Enzalutamide in Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic (M1) Castrate Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated: 9/21/2017
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC
ARMOR3-SV: A Phase 3, Randomized, Open Label, Multi-Center, Controlled Study of Galeterone Compared to Enzalutamide in Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic (M1) Castrate Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated:  9/21/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC
ARMOR3-SV: A Phase 3, Randomized, Open Label, Multi-Center, Controlled Study of Galeterone Compared to Enzalutamide in Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic (M1) Castrate Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated: 9/21/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC
ARMOR3-SV: A Phase 3, Randomized, Open Label, Multi-Center, Controlled Study of Galeterone Compared to Enzalutamide in Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic (M1) Castrate Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated:  9/21/2017
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC
ARMOR3-SV: A Phase 3, Randomized, Open Label, Multi-Center, Controlled Study of Galeterone Compared to Enzalutamide in Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic (M1) Castrate Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated: 9/21/2017
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials